March 9, 2015
Dopamine is a neurotransmitter that is important in locomotor control, reward circuitry, cognitive function, prolactin release, and a variety of other key physiological functions. Dopaminergic dysfunctions have been implicated in many disorders including Parkinson's disease, schizophrenia, addiction, and ADHD. Dopamine receptor agonists are of interest in terms of finding successful therapies for these disorders. However, current D1 and D2 receptor agonists can have adverse side effects depending on the level and timing of use.
Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.
Advantages
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
key physiological functions
finding successful therapies
d2 receptor agonists
technology summary researchers
dopamine receptor agonists
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium